BlackRock Inc. Raises Position in Agenus Inc (AGEN)

BlackRock Inc. raised its holdings in shares of Agenus Inc (NASDAQ:AGEN) by 16.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 6,846,902 shares of the biotechnology company’s stock after purchasing an additional 950,381 shares during the quarter. BlackRock Inc. owned 0.06% of Agenus worth $16,295,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Agenus by 272.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,105 shares of the biotechnology company’s stock worth $76,000 after buying an additional 23,493 shares in the last quarter. Virtu Financial LLC bought a new stake in Agenus during the third quarter worth approximately $105,000. Rhumbline Advisers boosted its holdings in Agenus by 50.3% during the fourth quarter. Rhumbline Advisers now owns 112,015 shares of the biotechnology company’s stock worth $267,000 after buying an additional 37,463 shares in the last quarter. Jefferies Group LLC boosted its holdings in Agenus by 171.2% during the third quarter. Jefferies Group LLC now owns 166,523 shares of the biotechnology company’s stock worth $356,000 after buying an additional 105,123 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in Agenus by 26.7% during the third quarter. Wells Fargo & Company MN now owns 941,284 shares of the biotechnology company’s stock worth $2,015,000 after buying an additional 198,247 shares in the last quarter. Hedge funds and other institutional investors own 28.39% of the company’s stock.

Agenus stock opened at $2.62 on Wednesday. Agenus Inc has a 52 week low of $1.54 and a 52 week high of $4.25. The company has a market capitalization of $357.67 million, a P/E ratio of -1.82 and a beta of 2.07.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.12). The company had revenue of $5.36 million for the quarter, compared to analysts’ expectations of $6.67 million. Analysts forecast that Agenus Inc will post -1.27 earnings per share for the current fiscal year.

A number of research firms recently commented on AGEN. Zacks Investment Research raised shares of Agenus from a “sell” rating to a “hold” rating in a research note on Thursday, January 24th. BidaskClub lowered shares of Agenus from a “hold” rating to a “sell” rating in a research note on Wednesday, April 10th. Finally, ValuEngine lowered shares of Agenus from a “buy” rating to a “hold” rating in a research note on Thursday, January 31st.

COPYRIGHT VIOLATION NOTICE: “BlackRock Inc. Raises Position in Agenus Inc (AGEN)” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.thelincolnianonline.com/2019/04/17/blackrock-inc-raises-position-in-agenus-inc-agen.html.

Agenus Profile

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

See Also: Net Margin – Understanding the Different Kinds of Profit

Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agenus Inc (NASDAQ:AGEN).

Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.